Volume 4, Issue 1: New HCV DAA Regimens, Retreatment and Optimizing Treatment of Genotype 2/3 Infection

e-Viral Hepatitis Review is a monthly CE series for nurses, nurse practitioners, and others involved in the care of patients with HepatitisIt provides updates on the latest research, best practices, and issues currently under debate, as well as a concise review of relevant journal literature.

(Volume 4, Issue 1)

Target Audience

Nurses and health care professionals involved in the care of patients with Hepatitis.

Learning Objectives

After participating in this activity, the participant will demonstrate the ability to: 

  • Evaluate the current treatment options for patients with GT2 and 3 HCV infection, including those with cirrhosis and prior treatment failure.
  • Discuss phase 3 clinical trial data using the new DAA regimen of grazoprevir/elbasvir.
  • Describe the limitations in currently available retreatment options for patients failing interferon-free DAA regimens, including the importance resistance may play in retreatment success.
Additional information
Contact email: 
Course summary
Available credit: 
  • 1.00 ANCC
  • 1.00 Attendance
Course opens: 
10/29/2015
Course expires: 
10/28/2017
Cost:
$0.00
David L. Wyles, MD
Associate Professor of Medicine
Division of Infectious Diseases
University of California San Diego
San Diego, CA

Available Credit

  • 1.00 ANCC
  • 1.00 Attendance

Accreditation Period

Course opens: 
10/29/2015
Course expires: 
10/28/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

Make sure your Adobe flash is updated by clicking HERE